Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Free full text

Full text

Publication Types

Journal Article

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Clinical Trial, Phase II

Clinical Trial, Phase I

Multicenter Study

Clinical Trial, Phase III

Research Support, N.I.H., Extramural

Comparative Study

Review

Systematic Review

Observational Study

Meta-Analysis

Research Support, U.S. Gov't, Non-P.H.S.

Research Support, U.S. Gov't, P.H.S.

Clinical Trial, Phase IV

Equivalence Trial

Research Support, N.I.H., Intramural

Comment

Publication Year

From

Quick links

Individual year

2026

2025

2024

2022

2021

2020

2019

2018

2017

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Immunogenicity, Vaccine""[mesh_terms]

86 Results

Searching titles within these results

Immunogenicity and safety of tetravalent dengue vaccines: a systematic review of clinical trials.

Lenyn D Montes-Sevilla, Paul E Hernández-Montes, Erick Ramírez-García, Edgar D Guzmán-Ríos, Marco F Flores-Reyes, Gilberto H Acosta-Gutiérrez, Osmara Morales-Hernández, Manuel I Girón-Pérez

Gaceta medica de Mexico 2025;161(3):227-236

Full Text

Abstract

In silico analysis and in vitro evaluation of immunogenic and immunomodulatory properties of promiscuous peptides derived from Leishmania infantum eukaryotic initiation factor.

Olga S Koutsoni, John G Routsias, Ioannis D Kyriazis, Mourad Barhoumi, Ikram Guizani, Athanassios Tsakris, Eleni Dotsika

Bioorganic & medicinal chemistry 2017;25(21):5904-5916

Free Full Text

Abstract

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Lulu C Bravo, Josefina C Carlos, Salvacion R Gatchalian, May Emmeline B Montellano, Charissa Fay Corazon B Tabora, Birgit Thierry-Carstensen, Pernille Nyholm Tingskov, Charlotte Sørensen, Henrik Wachmann, Ananda S Bandyopadhyay, Pernille Ingemann Nielsen, Mie Vestergaard Kusk

Vaccine 2021;38(3):530-538

Free Full Text

Abstract

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine.

Punnee Pitisuttithum, Viravarn Luvira

Expert review of vaccines 2024;23(1):283-293

Free Full Text

Abstract

Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system.

Huangwenxian Lan, Koji Hosomi, Jun Kunisawa

Vaccine 2020;37(42):6232-6239

Free Full Text

Abstract

Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants.

James A Church, Bernard Chasekwa, Sandra Rukobo, Margaret Govha, Benjamin Lee, Marya P Carmolli, Robert Ntozini, Kuda Mutasa, Monica M McNeal, Florence D Majo, Naume V Tavengwa, Beth D Kirkpatrick, Lawrence H Moulton, Jean H Humphrey, Andrew J Prendergast

Vaccine 2021;38(13):2870-2878

Free Full Text

Abstract

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Elmar A Joura, Angels Ulied, Corinne Vandermeulen, Milagrosa Rua Figueroa, Ilkka Seppä, Juan José Hernandez Aguado, Anitta Ahonen, Olaf Reich, Miia Virta, Antonino Perino, Merce Peris Tuser, Klaus Peters, Massimo Origoni, Francesco Raspagliesi, Wiebren A A Tjalma, Philippe Tummers, Linn Woelber, Pekka Nieminen, Pierre van Damme, Jalid Sehouli, Gabriel Fiol Ruiz, Sara Brucker, Tanja Fehm, Kyeongmi Cheon, Sonali Rawat, Alain Luxembourg, Frederick Wittke

Vaccine 2021;39(20):2800-2809

Full Text

Abstract

Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.

Jarir At Thobari, Wahyu Damayanti, Jonathan Hasian Haposan, Hera Nirwati, Kristy Iskandar, Julianita Fahmi, Rini Mulia Sari, Novilia Sjafri Bachtiar, Emma Watts, Julie E Bines, Yati Soenarto

Vaccine 2021;39(33):4651-4658

Free Full Text

Abstract

Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.

S Kannan, P Shaik Syed Ali, A Sheeza

European review for medical and pharmacological sciences 2022;25(24):8019-8022

Free Full Text

Abstract

A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.

Matt D T Hitchings, Derek A T Cummings, Rebecca F Grais, Sheila Isanaka

Vaccine 2021;38(51):8161-8166

Free Full Text

Abstract

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.

Desiree Witte, Amanda Handley, Khuzwayo C Jere, Nada Bogandovic-Sakran, Ashley Mpakiza, Ann Turner, Daniel Pavlic, Karen Boniface, Jonathan Mandolo, Darren Suryawijaya Ong, Rhian Bonnici, Frances Justice, Naor Bar-Zeev, Miren Iturriza-Gomara, Jim Ackland, Celeste M Donato, Daniel Cowley, Graeme Barnes, Nigel A Cunliffe, Julie E Bines

The Lancet. Infectious diseases 2022;22(5):668-678

Free Full Text

Abstract

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.

Maria Rosario Capeding, Edison Alberto, Arijit Sil, Tarun Saluja, Samuel Teshome, Deok Ryun Kim, Ju Yeon Park, Jae Seung Yang, Suchada Chinaworapong, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Seon-Young Yang, Dong Soo Ham, Ji Hwa Ryu, Julia Lynch, Jerome H Kim, Hun Kim, Jean-Louis Excler, T Anh Wartel, Sushant Sahastrabuddhe

Vaccine 2021;38(28):4476-4483

Free Full Text

Abstract

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.

Sean R Bennett, James M McCarty, Roshan Ramanathan, Jason Mendy, Jason S Richardson, Jonathan Smith, Jeff Alexander, Julie E Ledgerwood, Paul-André de Lame, Sarah Royalty Tredo, Kelly L Warfield, Lisa Bedell

The Lancet. Infectious diseases 2022;22(9):1343-1355

Full Text

Abstract

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Isabel Leal, Susan Guo, Jordi Navarro, Beatriz Mothe, Santiago Moreno, Adrian Curran, Arkaitz Imaz, Christian Brander, Ian McGowan, José Moltó, Ignacio de Los Santos, Juan Ambrosioni, Yuan Tian, Pere Domingo, Juan Berenguer, Juan González-García, Lucia Bailón, Julen Cadiñanos, Juan Carlos Lopez Bernaldo de Quirós, Susana Benet, Paula Suanzes, Carmen Busca, Leire Pérez-Latorre, Lucio Jesús García-Fraile, Gina Mejía-Abril, Jose M Miró, Sofía Scévola, Michelle Frankot, Daina Lim, Yanhui Cai, Elena Vendrame, Jeffrey J Wallin, Romas Geleziunas, Devi SenGupta, Yovaninna Alarcón-Soto, Alvaro Aranguen, Margarida Garcia-Garcia, Jose Ramón Arribas

Nature communications 2025;16(1):2146

Free Full Text

Abstract

Effect of processed aloe vera gel on immunogenicity in inactivated quadrivalent influenza vaccine and upper respiratory tract infection in healthy adults: A randomized double-blind placebo-controlled trial.

Jeong-Hwan Hwang, Mi-Ra Oh, Ji-Hyun Hwang, Eun-Kyung Choi, Su-Jin Jung, Eun-Jung Song, Erica Españo, Richard J Webby, Robert G Webster, Jeong-Ki Kim, Soo-Wan Chae

Phytomedicine : international journal of phytotherapy and phytopharmacology 2021;91():153668

Free Full Text

Abstract

Results: 1 – 15 / 86

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Immunogenicity, Vaccine""[mesh_terms]

Immunogenicity and safety of tetravalent dengue vaccines: a systematic review of clinical trials.

In silico analysis and in vitro evaluation of immunogenic and immunomodulatory properties of promiscuous peptides derived from Leishmania infantum eukaryotic initiation factor.

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine.

Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system.

Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.

Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.

A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Effect of processed aloe vera gel on immunogenicity in inactivated quadrivalent influenza vaccine and upper respiratory tract infection in healthy adults: A randomized double-blind placebo-controlled trial.

Results for
""Immunogenicity, Vaccine""[mesh_terms]

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.